{"id":"continuation-darbepoetinum","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thrombovascular events"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Injection site pain"},{"rate":"5-10","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL2108543","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darbepoetin alfa is a recombinant human erythropoietin analog engineered with two additional N-linked carbohydrate chains, which extends its half-life compared to epoetin alfa. It activates the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism increases hemoglobin levels and reduces the need for blood transfusions in anemic patients.","oneSentence":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:41.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with non-myeloid malignancies receiving chemotherapy"}]},"trialDetails":[{"nctId":"NCT00551603","phase":"PHASE4","title":"Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules","status":"WITHDRAWN","sponsor":"Anemia Working Group Romania","startDate":"2006-07","conditions":"Bio-Equivalency of 2 Treatment Schedules in HD Patients","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darbepo Group"],"phase":"marketed","status":"active","brandName":"continuation (darbepoetinum)","genericName":"continuation (darbepoetinum)","companyName":"Anemia Working Group Romania","companyId":"anemia-working-group-romania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with non-myeloid malignancies receiving chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}